XORTX Therapeutics Inc. (XRTX) NASDAQ
$0.59 -0.03 (-4.86%)
Market Cap: $8.91M
As of 02/03/23 04:00 PM EST. Market closed.
XORTX Therapeutics Inc. (XRTX) NASDAQ
$0.59 -0.03 (-4.86%)
Market Cap: $8.91M
As of 02/03/23 04:00 PM EST. Market closed.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage ... read more
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX Therapeutics is dedicated to developing medications to improve the quality of life and future health of patients. read less
Open in: 
Open in: